885031-86-7

Basic information

• Product Name: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine]-1-carboxylic acid, 1',2'-dihydro-2'-oxo-, 1,1-dimethylethyl ester
• CAS NO: 885031-86-7
• Molecular Formula: C16H21N3O3
• Molecular Weight: 303.361
• Mol File: 885031-86-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine]-1-carboxylic acid, 1',2'-dihydro-2'-oxo-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine]-1-carboxylic acid, 1',2'-dihydro-2'-oxo-, 1,1-dimethylethyl ester(885031-86-7)
• EPA Substance Registry System: Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine]-1-carboxylic acid, 1',2'-dihydro-2'-oxo-, 1,1-dimethylethyl ester(885031-86-7)

Safety Data

• Hazardous Substances Data: 885031-86-7(Hazardous Substances Data)

Upstream product

• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 1315335-16-0 2-chloro-4'-cyano-3',4',5',6'-tetrahydro-2'H-[3,4']-bipyridinyl-1'-carboxylic acid tert-butyl ester 
• 1315335-15-9 N-Boc-4-(2-chloropyridin-3-yl)piperidine-4-carboxamide 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 2942-59-8 2-chloronicotinic acid 
• 49609-84-9 2-Chloronicotinoyl chloride 
• 59-67-6 nicotinic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 883984-92-7 3,4-dihydroxyspiro[cyclopent-3-ene-1,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 5654-97-7 7-azaoxindole 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 884049-52-9 spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 

Downstream Products

• 1192834-15-3 C₂₈H₂₉N₃O₃ 
• 884049-52-9 spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1038866-43-1 spiro[piperidine-4,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one dihydrochloride 

Relevant articles and documents

A spirocyclic oxindole analogue: Synthesis and antitumor activities

A new synthesis of spirocyclic oxindole analogue spiro[piperidine-4, 3′-pyrrolo[2,3-b]pyridin]-2′(1′H)-one 1 is described. The key steps involve dialkylation of arylacetonitrile and cyclization of the azaoxindole ring by an intramolecular Buchwald-Hartwig amidation of carboxylic amide and aryl chloride. A small library was obtained by reductive amination of 1 with various aldehydes and was screened against human lung cancer cell A549, human liver cancer cell BEL7402, and human colon cancer cell HCT-8. The results show that most of the library compounds 2 have some inhibitory activities. 2-(Trifluoromethoxy) benzylic substituted spirocyclic azaoxindole 2e was identified as a nanomolar inhibitor against human lung cancer cell A-549 (IC50 = 50 nmol/L).

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.